Ketamine is classified as a dissociative anesthetic, a category of drug that produces a feeling of detachment from one’s body and surroundings rather than simply rendering someone unconscious. First developed in the 1960s as a safer alternative to phencyclidine (PCP), ketamine quickly became favored in operating rooms and battlefields because it produced fewer severe side effects while reliably blocking pain and awareness. But the dissociative state it creates is not a single, uniform experience. Depending on the dose, the route of administration, and the individual, ketamine can produce anything from mild emotional detachment to a complete sense of leaving the body, and understanding this spectrum matters for both the people who receive it clinically and those who encounter it recreationally.
What Dissociation Actually Feels Like on Ketamine
The word “dissociation” in everyday language suggests a mild spacing-out, but ketamine-induced dissociation is something considerably stranger. Studies using standardized questionnaires describe the experience as dominated by disembodiment and ego transcendence, with sensory disturbances layered on top. People report feeling separated from their own limbs, perceiving the room as distant or unreal, and losing the ordinary sense that their thoughts belong to them.
Researchers have mapped these subjective states into rough tiers linked to dosage. At lower intramuscular doses, around 0.25 to 0.5 mg/kg, the experience tends to involve mild shifts in body awareness, reduced emotional defenses, and feelings of comfort or relaxation. Moving up to around 0.75 to 1.5 mg/kg, people describe a full out-of-body experience with significantly weakened sense of self. At higher doses, in the range of 2 to 3 mg/kg intramuscularly, the experience can escalate to what some researchers describe as near-death or ego-dissolving transcendental states, involving a complete dissolution of boundaries between self and environment, a loss of time perception, and occasionally a sense of sacredness or cosmic significance.1PubMed Central. A unified model of ketamine’s dissociative and psychedelic properties This highest tier is what recreational users call the “K-hole,” though the clinical literature avoids that term.
These categories are not sharply divided. Set and setting, tolerance, body composition, and the speed of administration all blur the lines. Two people given the same dose can land in very different experiential territory. What is consistent across most reports is that dissociation, rather than hallucination in the visual-distortion sense, is the defining feature of ketamine’s altered state.2PubMed Central. Subanaesthetic ketamine and altered states of consciousness in humans
How the Brain Produces a Dissociative State
Ketamine’s primary pharmacological action is blocking a receptor called the NMDA receptor, which is one of the brain’s main receivers for the excitatory neurotransmitter glutamate. But that single fact does not explain why the result is dissociation rather than, say, simple sedation. The answer lies in which neurons get blocked first and what cascades from there.
Research from the Duman laboratory and others has established that ketamine preferentially blocks NMDA receptors on inhibitory neurons, the cells whose job is to dampen activity in surrounding circuits. When those inhibitory cells lose their excitatory drive, they release less of the neurotransmitter GABA, which normally keeps excitatory neurons in check. The result is a burst of glutamate signaling in circuits that were previously held in balance.3Neuropsychopharmacology. Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms This paradox, where blocking an excitatory receptor leads to more excitation, is central to both the dissociative experience and ketamine’s therapeutic effects.
At the level of brain networks, imaging studies show that ketamine disrupts the default mode network, the group of brain regions active during self-referential thought, daydreaming, and autobiographical memory. Specifically, connectivity drops between the medial prefrontal cortex and the rest of the default mode network.4PubMed Central. Ketamine effects on default mode network activity and vigilance: A randomized, placebo-controlled crossover simultaneous fMRI/EEG study At the same time, connectivity in regions involved in spatial awareness (the intraparietal cortices) increases, which may relate to the distorted body awareness people report.
As the dose climbs and sedation deepens, this disruption becomes more dramatic. The default mode network loses its usual anticorrelated push-pull relationship with sensory networks, and the salience network, which helps the brain decide what to pay attention to, also becomes partially suppressed. Executive control, auditory, and visual networks, by contrast, remain relatively intact.5Anesthesiology. Resting-state Network-specific Breakdown of Functional Connectivity during Ketamine Alteration of Consciousness in Volunteers This selective pattern helps explain why dissociation feels like the self has been unmade while sensory perception continues in distorted form, rather than a simple blackout.
Dose-Dependent Stabilization of Brain Activity
Dissociative symptoms do not just intensify linearly with dose; the brain’s electrical dynamics shift in a distinct, structured way. EEG recordings during ketamine administration show that the drug produces bursts of fast gamma oscillations, above 25 Hz, which at high doses become interrupted by slow delta oscillations in the 0.1 to 4 Hz range.6PubMed Central. Ketamine can produce oscillatory dynamics by engaging mechanisms dependent on the kinetics of NMDA receptors This alternating pattern of fast and slow waves is different from the gradual suppression seen with most sedatives and appears tied to the kinetics of NMDA receptor blocking.
Recent work has added another dimension: as dissociative symptoms intensify with increasing doses, cortical activity becomes progressively stabilized, especially at higher frequencies.7PubMed Central. The Administration of Ketamine Is Associated with Dose-Dependent Stabilization of Cortical Dynamics in Humans In plain terms, the brain’s moment-to-moment fluctuations settle into more rigid patterns. This may help explain the perceptual “freezing” and time distortion that people report at higher doses. The brain is not shutting down so much as locking into a constrained mode of operation.
Does Dissociation Matter for Treating Depression?
This is one of the most debated questions in ketamine psychiatry. Since the early 2000s, studies have shown that a single subanesthetic dose of ketamine, typically 0.5 mg/kg given intravenously over 40 minutes, can produce antidepressant effects within hours that last roughly a week, even in people whose depression has not responded to conventional medications.8PubMed Central. Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide This rapid action stands in stark contrast to traditional antidepressants, which take weeks to show results.
The mechanistic explanation for these effects focuses on that burst of glutamate signaling described earlier. The downstream consequence involves activation of molecular pathways that increase the formation of new dendritic spines, the tiny protrusions on neurons where synaptic connections form.9PubMed Central. Mechanisms of ketamine action as an antidepressant Depression is associated with a loss of these synaptic connections, especially in the prefrontal cortex, and ketamine appears to rapidly reverse that loss. This synaptic growth effect converges with what classical psychedelics like psilocybin and LSD do through their serotonin receptor targets, both drug classes promote structural and functional changes in prefrontal pyramidal neurons.10Trends in Pharmacological Sciences. Neuroplasticity as a convergent mechanism of action for ketamine and classical psychedelics
But whether the subjective dissociative experience is necessary for this biological process, or merely a side effect happening in parallel, remains genuinely unresolved. Some evidence points toward a link. One study found that depersonalization during ketamine infusion, the feeling of being outside or detached from your own self, was positively related to improvement in depression scores across multiple time points. Derealization, the feeling that the world around you is unreal, showed a weaker and less consistent relationship, while amnesia had no relationship at all.11PubMed Central. Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression In other words, not all features of dissociation track with getting better; something specific about the self-detachment component may be relevant.
Separately, in a real-world study combining ketamine with psychotherapy, the degree of ego dissolution during treatment correlated with both symptom improvement and psychological insight.12PubMed. Ketamine combined with psychotherapy for treatment-resistant depression: Real-world outcomes and the role of subjective experience This has fueled an emerging approach called ketamine-assisted psychotherapy, where the dissociative state is not treated as an inconvenient side effect but as the therapeutic window itself. In these protocols, an altered state and the patient’s integration of the experience afterward are central to the treatment.13npj mental health research. A scoping review: ketamine or esketamine when used to assist psychotherapy or in combination with psychotherapy for the management of depression in adults
The counterargument is that the dose-ranging evidence does not always support dissociation as necessary. Dose-ranging trials have found that 0.5 mg/kg and 1.0 mg/kg produce clear antidepressant effects while lower doses do not.14Molecular Psychiatry. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD) The difficulty is that higher doses also produce more dissociation, so separating the pharmacological effect from the experiential effect is a chicken-and-egg problem that has not been cleanly resolved.
Sub-Dissociative Ketamine in Emergency Medicine
Not every clinical use of ketamine wants the dissociative state. Emergency departments have increasingly adopted sub-dissociative dose ketamine, generally below 0.3 mg/kg intravenously, as an alternative or supplement to opioids for acute pain. At these doses, patients remain alert and oriented, without the detachment and perceptual distortions of higher doses. Studies have found that even this low dose produces significant reductions in pain scores within 60 minutes and decreases the need for additional opioid painkillers afterward.15PubMed. Efficacy of analgesic and sub-dissociative dose ketamine for acute pain in the emergency department
This opioid-sparing property has made sub-dissociative ketamine attractive during the ongoing opioid crisis. It can be given by intravenous push, slow infusion, or continuous infusion, and it works across a variety of painful conditions including trauma, abdominal pain, and musculoskeletal injuries.16PubMed Central. Sub-dissociative dose ketamine administration for managing pain in the emergency department Side effects at these doses tend to be mild: dizziness, slight nausea, and occasionally a brief feeling of being “floaty.” Patients rarely describe the full dissociative experience associated with higher doses.
Esketamine and Arketamine Have Different Dissociative Profiles
The ketamine molecule exists in two mirror-image forms, called S-ketamine (esketamine) and R-ketamine (arketamine). Racemic ketamine, the version used in most clinical and recreational contexts, is a 50/50 mixture of both. The two forms differ meaningfully in their pharmacological profiles, including how much dissociation they produce.
Esketamine binds roughly three to four times more tightly to the NMDA receptor than arketamine does, giving it about three times the analgesic strength and 1.5 times the anesthetic potency.17PubMed Central. Ketamine, Esketamine, and Arketamine: Their Mechanisms of Action and Applications in the Treatment of Depression and Alleviation of Depressive Symptoms Esketamine is the form that was approved as a nasal spray (marketed as Spravato) for treatment-resistant depression, and it is the form more strongly associated with dissociative side effects. Arketamine, by contrast, shows lower rates of dissociative and psychosis-like effects across studies that have examined it in humans.18PubMed. Arketamine: a scoping review of its use in humans This has generated considerable interest in arketamine as a possible antidepressant with fewer perceptual side effects, along with potential applications in neurological conditions like Alzheimer’s and Parkinson’s disease. The catch is that arketamine’s clinical evidence base is still thin compared to esketamine’s, and it remains unclear whether its reduced dissociative profile comes at the cost of reduced efficacy.
How the drug is administered also shapes the experience. A pharmacokinetic study in healthy volunteers found that oral ketamine tablets had a bioavailability of roughly 20%, sublingual tablets and suppositories around 30%, and nasal spray about 45%. Injection, by contrast, delivers the drug with much higher efficiency.19PubMed. Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers Lower bioavailability means lower peak blood levels at a given dose, which translates to less dissociation but also potentially less therapeutic effect. This is one reason different routes of administration can produce very different subjective experiences even with comparable nominal doses.
Emergence Reactions and Recovery Agitation
One of ketamine’s best-known clinical headaches is the emergence reaction: agitation, confusion, vivid dreams, or delirium that can occur as the dissociative state wears off and the patient returns to normal consciousness. This phenomenon is distinct from the dissociative experience itself. It tends to happen in the transition zone between deep sedation and full wakefulness, as though the brain’s networks are reconnecting in a disordered way.
The incidence varies widely across studies and populations. In a study of adults undergoing procedural sedation in the emergency department, combining ketamine with either dexmedetomidine or propofol reduced the incidence and severity of recovery agitation compared to ketamine alone.20PubMed. A comparative study of dexmedetomidine and propofol to prevent recovery agitation in adults undergoing procedural sedation with ketamine: A randomized double-blind clinical trial In children, who are frequent recipients of ketamine anesthesia for minor procedures, pretreatment with haloperidol has been shown to decrease postoperative emergence delirium.21PubMed Central. Does Haloperidol Prophylaxis Reduce Ketamine-Induced Emergence Delirium in Children?
Interestingly, when ketamine is used as a supplemental agent during surgeries that already involve other anesthetics, the picture becomes less clear. An observational study of patients undergoing laparoscopic surgery found no significant difference in emergence delirium rates between those who received intraoperative ketamine and those who did not.22Brazilian Journal of Anesthesiology (English Edition). Association between intraoperative ketamine and the incidence of emergence delirium in laparoscopic surgeries: an observational study The context matters: a small adjunctive dose of ketamine during a multi-drug anesthetic regimen is pharmacologically very different from a full dissociative dose given alone.
Urinary Tract Damage From Repeated Use
The most serious physical risk specific to ketamine, especially with frequent recreational use, is damage to the urinary tract. This condition, often called ketamine-induced cystitis, was first recognized in the late 2000s as recreational ketamine use expanded globally. Regular use increases the risk of cystitis symptoms by roughly three to four times, and the progression can be relentless if use continues.23PubMed Central. Ketamine-Induced Cystitis: A Comprehensive Review of the Urologic Effects of This Psychoactive Drug
The typical pattern starts with irritable bladder symptoms: increased frequency and urgency of urination. Over time, these progress to painful urination, reduced bladder capacity, and eventually ulceration of the bladder wall. In severe cases, the damage extends beyond the bladder to include narrowing of the ureters, reflux of urine toward the kidneys, and kidney failure.24PubMed Central. Pathophysiology, clinical presentation, and management of ketamine-induced cystitis Stopping ketamine use usually improves symptoms, but severe cases can involve irreversible bladder damage, and some patients require surgical intervention.25PubMed Central. Ketamine bladder syndrome: an important differential diagnosis when assessing a patient with persistent lower urinary tract symptoms
This risk is largely associated with recreational patterns of use: frequent doses, often daily, over months or years. The clinical doses used for depression treatment or procedural sedation are far lower in both frequency and total exposure, and ketamine-induced cystitis has not emerged as a significant concern in those settings. Still, as ketamine clinics proliferate and some patients receive repeated infusions over extended periods, urologists have flagged this as a risk worth monitoring.
Addiction Potential and Dopamine
Ketamine does carry abuse potential, which creates tension with its expanding therapeutic use. The reinforcing effects appear to involve not just NMDA receptor blockade but also downstream effects on the dopamine system. The proposed mechanism is that ketamine blocks NMDA receptors on inhibitory neurons within the thalamic reticular nucleus, disinhibiting dopamine neurons and increasing dopamine release.26PubMed Central. Ketamine abuse potential and use disorder This dopamine boost contributes to the pleasurable and motivationally reinforcing aspects of the experience, which are separate from the dissociative phenomenology but occur alongside it.
Tolerance develops with repeated use, and a withdrawal syndrome, though less physically dramatic than opioid or alcohol withdrawal, can involve cravings, anxiety, and low mood. The populations most at risk for ketamine use disorder are recreational users taking the drug frequently at high doses, rather than patients receiving supervised clinical infusions on a scheduled basis. Even so, the therapeutic community has been cautious about at-home ketamine prescribing, which has expanded through telehealth platforms in recent years, because the lack of direct supervision introduces more opportunity for misuse.
Neurotoxicity Questions Remain Partially Unresolved
In the 1980s and 1990s, research by John Olney and colleagues found that NMDA receptor antagonists, including ketamine, could cause a pattern of cell injury in certain brain regions of rats, now called Olney’s lesions. This finding raised alarms about the safety of repeated ketamine exposure. However, subsequent studies using different rat strains, routes of administration, and dosing protocols have not always replicated these findings. One direct comparison found that ketamine did not induce Olney’s lesions under their specific experimental conditions, in contrast to the original reports, and suggested that differences in rat strain and injection route could explain the discrepancy.27PubMed Central. A comparison of the pharmacokinetics and NMDAR antagonism-associated neurotoxicity of ketamine, (2R,6R)-hydroxynorketamine and MK-801
Whether ketamine causes meaningful neurotoxicity in humans at clinical doses is an open question that decades of surgical use have not definitively settled in one direction. Millions of anesthesia cases have not produced obvious signals of brain damage, but the long-term cognitive effects of repeated sub-anesthetic dosing for depression, delivered over months or years, are simply not yet well characterized. The developing brain is a particular concern: while ketamine is widely and safely used for pediatric procedural sedation in the short term, animal studies showing neuronal apoptosis in young animals have kept researchers attentive to potential risks in prolonged or repeated neonatal exposure.
From Veterinary Staple to Human Medicine and Back
Ketamine occupies an unusual place in pharmacology because it has maintained a continuous, prominent role in veterinary medicine even as its human applications have shifted. In veterinary settings, ketamine is valued for its wide margin of safety across species. It can be used in creatures ranging from small rodents to large mammals without the respiratory depression that makes many other anesthetics dangerous without intubation. A study comparing ketamine alone versus ketamine combined with medetomidine and butorphanol for anesthetizing wild badgers illustrates its veterinary versatility: the combination substantially reduced adverse effects like excessive salivation, sneezing, and rough recoveries while extending the duration of anesthesia.28PubMed Central. Experimental comparison of ketamine with a combination of ketamine, butorphanol and medetomidine for general anaesthesia of the Eurasian badger (Meles meles L.)
The dissociative state in animals presents its own interpretive challenges. Unlike humans, animals cannot report feeling detached from their bodies or experiencing ego dissolution. Veterinarians instead rely on behavioral markers: a characteristic cataleptic posture, eyes remaining open with a fixed stare, and exaggerated responses to sensory stimuli during recovery. These observations suggest that something functionally analogous to dissociation occurs across mammalian species, but the subjective quality of it, if any, remains unknown. Ketamine’s origin as a veterinary drug and its continued dominance there is a reminder that dissociation was initially viewed as an acceptable trade-off for safe anesthesia, not as a therapeutic feature. The shift toward valuing the dissociative experience itself, whether for depression treatment or psychotherapy, represents a conceptual reversal that would have puzzled the pharmacologists who first synthesized the molecule in 1962.